ASCO: Pembrolizumab Ups DFS in High-Risk Resected Clear-Cell RCC
Estimated DFS rate 77.3 and 68.1 percent at 24 months with pembrolizumab versus placebo; benefit consistent across subgroups
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.